View Future GrowthKBC Corporation 과거 순이익 실적과거 기준 점검 0/6KBC 의 수입은 연평균 -66.5%의 비율로 감소해 온 반면, Chemicals 산업은 연평균 5.6%의 비율로 감소했습니다. 매출은 연평균 11.8%의 비율로 감소해 왔습니다.핵심 정보-66.49%순이익 성장률-66.48%주당순이익(EPS) 성장률Chemicals 산업 성장률12.10%매출 성장률-11.76%자기자본이익률-32.88%순이익률-149.22%다음 순이익 업데이트26 May 2026최근 과거 실적 업데이트공시 • Mar 30KBC Corporation, Ltd. to Report Q1, 2026 Results on Apr 29, 2026KBC Corporation, Ltd. announced that they will report Q1, 2026 results on Apr 29, 2026공시 • Dec 26KBC Corporation, Ltd. to Report Fiscal Year 2025 Results on Apr 29, 2026KBC Corporation, Ltd. announced that they will report fiscal year 2025 results on Apr 29, 2026공시 • Sep 30KBC Corporation, Ltd. to Report Q3, 2025 Results on Oct 30, 2025KBC Corporation, Ltd. announced that they will report Q3, 2025 results on Oct 30, 2025공시 • Jun 30KBC Corporation, Ltd. to Report First Half, 2025 Results on Aug 29, 2025KBC Corporation, Ltd. announced that they will report first half, 2025 results on Aug 29, 2025공시 • Mar 28KBC Corporation, Ltd. to Report Q1, 2025 Results on Apr 29, 2025KBC Corporation, Ltd. announced that they will report Q1, 2025 results on Apr 29, 2025공시 • Dec 27KBC Corporation, Ltd. to Report Fiscal Year 2024 Results on Apr 29, 2025KBC Corporation, Ltd. announced that they will report fiscal year 2024 results on Apr 29, 2025모든 업데이트 보기Recent updatesBoard Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent Director Jie Li was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.공시 • Apr 29KBC Corporation, Ltd., Annual General Meeting, May 20, 2026KBC Corporation, Ltd., Annual General Meeting, May 20, 2026, at 14:00 China Standard Time. Location: 1F, No. 79, Xiaoshitang Road, Yuelu District, Changsha, Hunan China공시 • Mar 30KBC Corporation, Ltd. to Report Q1, 2026 Results on Apr 29, 2026KBC Corporation, Ltd. announced that they will report Q1, 2026 results on Apr 29, 2026공시 • Dec 26KBC Corporation, Ltd. to Report Fiscal Year 2025 Results on Apr 29, 2026KBC Corporation, Ltd. announced that they will report fiscal year 2025 results on Apr 29, 2026공시 • Sep 30KBC Corporation, Ltd. to Report Q3, 2025 Results on Oct 30, 2025KBC Corporation, Ltd. announced that they will report Q3, 2025 results on Oct 30, 2025공시 • Jun 30KBC Corporation, Ltd. to Report First Half, 2025 Results on Aug 29, 2025KBC Corporation, Ltd. announced that they will report first half, 2025 results on Aug 29, 2025공시 • Apr 29KBC Corporation, Ltd., Annual General Meeting, May 20, 2025KBC Corporation, Ltd., Annual General Meeting, May 20, 2025, at 14:00 China Standard Time.공시 • Mar 28KBC Corporation, Ltd. to Report Q1, 2025 Results on Apr 29, 2025KBC Corporation, Ltd. announced that they will report Q1, 2025 results on Apr 29, 2025공시 • Dec 27KBC Corporation, Ltd. to Report Fiscal Year 2024 Results on Apr 29, 2025KBC Corporation, Ltd. announced that they will report fiscal year 2024 results on Apr 29, 2025Reported Earnings • Oct 30Third quarter 2024 earnings released: CN¥0.21 loss per share (vs CN¥0.14 profit in 3Q 2023)Third quarter 2024 results: CN¥0.21 loss per share (down from CN¥0.14 profit in 3Q 2023). Revenue: CN¥97.3m (down 64% from 3Q 2023). Net loss: CN¥42.8m (down 248% from profit in 3Q 2023). Revenue is forecast to grow 69% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China.New Risk • Sep 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.공시 • Sep 30KBC Corporation, Ltd. to Report Q3, 2024 Results on Oct 30, 2024KBC Corporation, Ltd. announced that they will report Q3, 2024 results on Oct 30, 2024공시 • Aug 09KBC Corporation, Ltd. (SHSE:688598) commences an Equity Buyback Plan for CNY 20 million worth of its shares, under the authorization approved on August 6, 2024.KBC Corporation, Ltd. (SHSE:688598) commences share repurchases on August 8, 2024, under the program mandated by the shareholders in the Extraordinary General Meeting held on August 6, 2024. As per the mandate, the company is authorized to repurchase to repurchase CNY 20 million worth of its common shares. The shares will be repurchased at a price of not more than CNY 35 per share. The shares repurchased will be used to reduce registered capital, used for employee stock ownership plan or equity incentive, used to convert company convertible bonds and to maintain company value and shareholder rights. The program will be funded out of the company's own funds. The program will be valid till 1 months from the date of approval by shareholders, i.e., till September 5, 2024.공시 • Jun 28KBC Corporation, Ltd. to Report First Half, 2024 Results on Aug 30, 2024KBC Corporation, Ltd. announced that they will report first half, 2024 results on Aug 30, 2024New Risk • May 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (31% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (8.9% average weekly change). Profit margins are more than 30% lower than last year (3.1% net profit margin).공시 • Apr 30KBC Corporation, Ltd., Annual General Meeting, May 20, 2024KBC Corporation, Ltd., Annual General Meeting, May 20, 2024, at 14:00 China Standard Time. Location: 1F, No. 79, Xiaoshitang Road, Yuelu District, Changsha, Hunan ChinaReported Earnings • Apr 29Full year 2023 earnings released: EPS: CN¥1.46 (vs CN¥4.36 in FY 2022)Full year 2023 results: EPS: CN¥1.46 (down from CN¥4.36 in FY 2022). Revenue: CN¥1.07b (down 26% from FY 2022). Net income: CN¥202.5m (down 63% from FY 2022). Profit margin: 19% (down from 38% in FY 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 65% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Chemicals industry in China.Valuation Update With 7 Day Price Move • Apr 16Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to CN¥42.45, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 15x in the Chemicals industry in China. Total loss to shareholders of 66% over the past year.공시 • Mar 29KBC Corporation, Ltd. to Report Q1, 2024 Results on Apr 29, 2024KBC Corporation, Ltd. announced that they will report Q1, 2024 results on Apr 29, 2024Valuation Update With 7 Day Price Move • Mar 14Investor sentiment improves as stock rises 15%After last week's 15% share price gain to CN¥55.50, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 15x in the Chemicals industry in China. Total loss to shareholders of 54% over the past year. Simply Wall St's valuation model estimates the intrinsic value at CN¥96.72 per share.공시 • Feb 27KBC Corporation, Ltd. (SHSE:688598) commences an Equity Buyback Plan for CNY 100 million worth of its shares, under the authorization approved on February 23, 2024.KBC Corporation, Ltd. (SHSE:688598) commences share repurchases on February 26, 2024, under the program mandated by the shareholders in the Extraordinary General Meeting held on February 23, 2023. As per the mandate, the company is authorized to repurchase to repurchase CNY 100 million worth of its common shares. The shares will be repurchased at a price of not more than CNY 90 per share. The repurchased shares will be cancelled. The program will be funded out of the company's own funds. The program will be valid till 1 months from the date of approval by shareholders.Reported Earnings • Feb 24Full year 2023 earnings released: EPS: CN¥1.46 (vs CN¥4.36 in FY 2022)Full year 2023 results: EPS: CN¥1.46 (down from CN¥4.36 in FY 2022). Revenue: CN¥1.07b (down 26% from FY 2022). Net income: CN¥203.3m (down 63% from FY 2022). Profit margin: 19% (down from 38% in FY 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 55% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Chemicals industry in China.Valuation Update With 7 Day Price Move • Jan 31Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to CN¥45.84, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 14x in the Chemicals industry in China. Total loss to shareholders of 72% over the past year. Simply Wall St's valuation model estimates the intrinsic value at CN¥88.43 per share.New Risk • Jan 22New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Chinese stocks, typically moving 7.8% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (7.8% average weekly change). High level of non-cash earnings (41% accrual ratio).Buying Opportunity • Dec 11Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 11%. The fair value is estimated to be CN¥91.03, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 31% over the last 3 years. Earnings per share has grown by 23%. Revenue is forecast to grow by 201% in 2 years. Earnings is forecast to grow by 156% in the next 2 years.New Risk • Nov 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (41% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (6.9% average weekly change).Reported Earnings • Oct 24Third quarter 2023 earnings released: EPS: CN¥0.21 (vs CN¥0.98 in 3Q 2022)Third quarter 2023 results: EPS: CN¥0.21 (down from CN¥0.98 in 3Q 2022). Revenue: CN¥271.1m (down 9.7% from 3Q 2022). Net income: CN¥28.8m (down 78% from 3Q 2022). Profit margin: 11% (down from 43% in 3Q 2022). Revenue is forecast to grow 47% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Chemicals industry in China.공시 • Sep 27KBC Corporation, Ltd. (SHSE:688598) announces an Equity Buyback for CNY 100 million worth of its shares.KBC Corporation, Ltd. (SHSE:688598) announces a share repurchase program. Under the program, the company will repurchase up to CNY 100 million worth of its shares. The program will be valid for a period of 3 months.Reported Earnings • Aug 15Second quarter 2023 earnings released: EPS: CN¥1.20 (vs CN¥1.39 in 2Q 2022)Second quarter 2023 results: EPS: CN¥1.20 (down from CN¥1.39 in 2Q 2022). Revenue: CN¥304.6m (down 23% from 2Q 2022). Net income: CN¥165.1m (flat on 2Q 2022). Profit margin: 54% (up from 42% in 2Q 2022). Revenue is forecast to grow 40% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China.공시 • Jun 28KBC Corporation, Ltd. to Report First Half, 2023 Results on Aug 29, 2023KBC Corporation, Ltd. announced that they will report first half, 2023 results on Aug 29, 2023New Risk • Jun 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (53% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (6.8% average weekly change). Shareholders have been diluted in the past year (17% increase in shares outstanding).공시 • May 30KBC Corporation, Ltd. (SHSE:688598) announces an Equity Buyback for CNY 100 million worth of its shares.KBC Corporation, Ltd. (SHSE:688598) announces a share repurchase program. Under the program, the company will repurchase up to CNY 100 million worth of its shares. The program will be valid for a period of 3 months.Reported Earnings • Apr 22Full year 2022 earnings released: EPS: CN¥6.45 (vs CN¥6.26 in FY 2021)Full year 2022 results: EPS: CN¥6.45 (up from CN¥6.26 in FY 2021). Revenue: CN¥1.45b (up 8.4% from FY 2021). Net income: CN¥551.2m (up 10.0% from FY 2021). Profit margin: 38% (in line with FY 2021). Revenue is forecast to grow 44% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Chemicals industry in China.Reported Earnings • Mar 01Full year 2022 earnings released: EPS: CN¥6.45 (vs CN¥6.26 in FY 2021)Full year 2022 results: EPS: CN¥6.45 (up from CN¥6.26 in FY 2021). Revenue: CN¥1.45b (up 8.4% from FY 2021). Net income: CN¥551.2m (up 10.0% from FY 2021). Profit margin: 38% (in line with FY 2021). Revenue is forecast to grow 38% p.a. on average during the next 2 years, compared to a 19% growth forecast for the Chemicals industry in China.Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent Director Hongbo Liu was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Valuation Update With 7 Day Price Move • Nov 05Investor sentiment improved over the past weekAfter last week's 15% share price gain to CN¥265, the stock trades at a forward P/E ratio of 31x. Average forward P/E is 15x in the Chemicals industry in China.Reported Earnings • Oct 30Third quarter 2022 earnings released: EPS: CN¥1.46 (vs CN¥1.63 in 3Q 2021)Third quarter 2022 results: EPS: CN¥1.46 (down from CN¥1.63 in 3Q 2021). Revenue: CN¥300.2m (down 20% from 3Q 2021). Net income: CN¥128.8m (down 1.3% from 3Q 2021). Profit margin: 43% (up from 35% in 3Q 2021). The increase in margin was driven by lower expenses. Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China.Reported Earnings • Aug 29Second quarter 2022 earnings released: EPS: CN¥2.06 (vs CN¥1.58 in 2Q 2021)Second quarter 2022 results: EPS: CN¥2.06 (up from CN¥1.58 in 2Q 2021). Revenue: CN¥396.3m (up 27% from 2Q 2021). Net income: CN¥165.3m (up 30% from 2Q 2021). Profit margin: 42% (up from 41% in 2Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 26%, compared to a 40% growth forecast for the Chemicals industry in China.Valuation Update With 7 Day Price Move • Aug 02Investor sentiment improved over the past weekAfter last week's 15% share price gain to CN¥381, the stock trades at a forward P/E ratio of 44x. Average forward P/E is 18x in the Chemicals industry in China.Valuation Update With 7 Day Price Move • Jul 16Investor sentiment improved over the past weekAfter last week's 17% share price gain to CN¥330, the stock trades at a forward P/E ratio of 38x. Average forward P/E is 17x in the Chemicals industry in China.Valuation Update With 7 Day Price Move • May 02Investor sentiment improved over the past weekAfter last week's 17% share price gain to CN¥214, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 15x in the Chemicals industry in China.Reported Earnings • Apr 27First quarter 2022 earnings released: EPS: CN¥2.53 (vs CN¥0.97 in 1Q 2021)First quarter 2022 results: EPS: CN¥2.53 (up from CN¥0.97 in 1Q 2021). Revenue: CN¥450.2m (up 126% from 1Q 2021). Net income: CN¥202.7m (up 163% from 1Q 2021). Profit margin: 45% (up from 39% in 1Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 21%, compared to a 43% growth forecast for the industry in China.Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent Director Hongbo Liu was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Valuation Update With 7 Day Price Move • Mar 08Investor sentiment deteriorated over the past weekAfter last week's 21% share price decline to CN¥222, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 18x in the Chemicals industry in China.Reported Earnings • Feb 27Full year 2021 earnings: EPS in line with analyst expectations despite revenue beatFull year 2021 results: EPS: CN¥6.26 (up from CN¥2.35 in FY 2020). Revenue: CN¥1.34b (up 214% from FY 2020). Net income: CN¥501.1m (up 197% from FY 2020). Profit margin: 38% (down from 40% in FY 2020). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 9.7%. Over the next year, revenue is forecast to grow 27%, compared to a 47% growth forecast for the industry in China.Valuation Update With 7 Day Price Move • Jan 11Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to CN¥298, the stock trades at a forward P/E ratio of 43x. Average forward P/E is 20x in the Chemicals industry in China.매출 및 비용 세부 내역KBC Corporation가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이XSSC:688598 매출, 비용 및 순이익 (CNY Millions)날짜매출순이익일반관리비연구개발비31 Mar 26854-1,2759516431 Dec 25803-1,2818713830 Sep 25715-9458410030 Jun 25604-880817931 Mar 25494-846827431 Dec 24537-815879130 Sep 24634-2557711730 Jun 24808-18410413631 Mar 249723010014631 Dec 231,07220210315230 Sep 231,18136615016830 Jun 231,21046613316931 Mar 231,30246715616731 Dec 221,45055116915430 Sep 221,59766315611730 Jun 221,67266517910131 Mar 221,5896271678031 Dec 211,3385011496530 Sep 211,0263891235730 Jun 21753299904631 Mar 21534204683931 Dec 20426169543530 Sep 20338121533630 Jun 20303104433231 Mar 2026793373131 Dec 1924078362931 Dec 1818054272831 Dec 17142293315양질의 수익: 688598 은(는) 현재 수익성이 없습니다.이익 마진 증가: 688598는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: 688598은 수익성이 없으며 지난 5년 동안 손실이 연평균 66.5% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 688598의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: 688598은 수익성이 없어 지난 해 수익 성장률을 Chemicals 업계(3.7%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: 688598는 현재 수익성이 없으므로 자본 수익률이 음수(-32.88%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YMaterials 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/22 03:38종가2026/05/22 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스KBC Corporation, Ltd.는 5명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Xianfan ChenChina International Capital Corporation LimitedBai Qiao XuHaitong International Research LimitedJun LiuHuatai Research2명의 분석가 더 보기
공시 • Mar 30KBC Corporation, Ltd. to Report Q1, 2026 Results on Apr 29, 2026KBC Corporation, Ltd. announced that they will report Q1, 2026 results on Apr 29, 2026
공시 • Dec 26KBC Corporation, Ltd. to Report Fiscal Year 2025 Results on Apr 29, 2026KBC Corporation, Ltd. announced that they will report fiscal year 2025 results on Apr 29, 2026
공시 • Sep 30KBC Corporation, Ltd. to Report Q3, 2025 Results on Oct 30, 2025KBC Corporation, Ltd. announced that they will report Q3, 2025 results on Oct 30, 2025
공시 • Jun 30KBC Corporation, Ltd. to Report First Half, 2025 Results on Aug 29, 2025KBC Corporation, Ltd. announced that they will report first half, 2025 results on Aug 29, 2025
공시 • Mar 28KBC Corporation, Ltd. to Report Q1, 2025 Results on Apr 29, 2025KBC Corporation, Ltd. announced that they will report Q1, 2025 results on Apr 29, 2025
공시 • Dec 27KBC Corporation, Ltd. to Report Fiscal Year 2024 Results on Apr 29, 2025KBC Corporation, Ltd. announced that they will report fiscal year 2024 results on Apr 29, 2025
Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent Director Jie Li was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
공시 • Apr 29KBC Corporation, Ltd., Annual General Meeting, May 20, 2026KBC Corporation, Ltd., Annual General Meeting, May 20, 2026, at 14:00 China Standard Time. Location: 1F, No. 79, Xiaoshitang Road, Yuelu District, Changsha, Hunan China
공시 • Mar 30KBC Corporation, Ltd. to Report Q1, 2026 Results on Apr 29, 2026KBC Corporation, Ltd. announced that they will report Q1, 2026 results on Apr 29, 2026
공시 • Dec 26KBC Corporation, Ltd. to Report Fiscal Year 2025 Results on Apr 29, 2026KBC Corporation, Ltd. announced that they will report fiscal year 2025 results on Apr 29, 2026
공시 • Sep 30KBC Corporation, Ltd. to Report Q3, 2025 Results on Oct 30, 2025KBC Corporation, Ltd. announced that they will report Q3, 2025 results on Oct 30, 2025
공시 • Jun 30KBC Corporation, Ltd. to Report First Half, 2025 Results on Aug 29, 2025KBC Corporation, Ltd. announced that they will report first half, 2025 results on Aug 29, 2025
공시 • Apr 29KBC Corporation, Ltd., Annual General Meeting, May 20, 2025KBC Corporation, Ltd., Annual General Meeting, May 20, 2025, at 14:00 China Standard Time.
공시 • Mar 28KBC Corporation, Ltd. to Report Q1, 2025 Results on Apr 29, 2025KBC Corporation, Ltd. announced that they will report Q1, 2025 results on Apr 29, 2025
공시 • Dec 27KBC Corporation, Ltd. to Report Fiscal Year 2024 Results on Apr 29, 2025KBC Corporation, Ltd. announced that they will report fiscal year 2024 results on Apr 29, 2025
Reported Earnings • Oct 30Third quarter 2024 earnings released: CN¥0.21 loss per share (vs CN¥0.14 profit in 3Q 2023)Third quarter 2024 results: CN¥0.21 loss per share (down from CN¥0.14 profit in 3Q 2023). Revenue: CN¥97.3m (down 64% from 3Q 2023). Net loss: CN¥42.8m (down 248% from profit in 3Q 2023). Revenue is forecast to grow 69% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China.
New Risk • Sep 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
공시 • Sep 30KBC Corporation, Ltd. to Report Q3, 2024 Results on Oct 30, 2024KBC Corporation, Ltd. announced that they will report Q3, 2024 results on Oct 30, 2024
공시 • Aug 09KBC Corporation, Ltd. (SHSE:688598) commences an Equity Buyback Plan for CNY 20 million worth of its shares, under the authorization approved on August 6, 2024.KBC Corporation, Ltd. (SHSE:688598) commences share repurchases on August 8, 2024, under the program mandated by the shareholders in the Extraordinary General Meeting held on August 6, 2024. As per the mandate, the company is authorized to repurchase to repurchase CNY 20 million worth of its common shares. The shares will be repurchased at a price of not more than CNY 35 per share. The shares repurchased will be used to reduce registered capital, used for employee stock ownership plan or equity incentive, used to convert company convertible bonds and to maintain company value and shareholder rights. The program will be funded out of the company's own funds. The program will be valid till 1 months from the date of approval by shareholders, i.e., till September 5, 2024.
공시 • Jun 28KBC Corporation, Ltd. to Report First Half, 2024 Results on Aug 30, 2024KBC Corporation, Ltd. announced that they will report first half, 2024 results on Aug 30, 2024
New Risk • May 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (31% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (8.9% average weekly change). Profit margins are more than 30% lower than last year (3.1% net profit margin).
공시 • Apr 30KBC Corporation, Ltd., Annual General Meeting, May 20, 2024KBC Corporation, Ltd., Annual General Meeting, May 20, 2024, at 14:00 China Standard Time. Location: 1F, No. 79, Xiaoshitang Road, Yuelu District, Changsha, Hunan China
Reported Earnings • Apr 29Full year 2023 earnings released: EPS: CN¥1.46 (vs CN¥4.36 in FY 2022)Full year 2023 results: EPS: CN¥1.46 (down from CN¥4.36 in FY 2022). Revenue: CN¥1.07b (down 26% from FY 2022). Net income: CN¥202.5m (down 63% from FY 2022). Profit margin: 19% (down from 38% in FY 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 65% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Chemicals industry in China.
Valuation Update With 7 Day Price Move • Apr 16Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to CN¥42.45, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 15x in the Chemicals industry in China. Total loss to shareholders of 66% over the past year.
공시 • Mar 29KBC Corporation, Ltd. to Report Q1, 2024 Results on Apr 29, 2024KBC Corporation, Ltd. announced that they will report Q1, 2024 results on Apr 29, 2024
Valuation Update With 7 Day Price Move • Mar 14Investor sentiment improves as stock rises 15%After last week's 15% share price gain to CN¥55.50, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 15x in the Chemicals industry in China. Total loss to shareholders of 54% over the past year. Simply Wall St's valuation model estimates the intrinsic value at CN¥96.72 per share.
공시 • Feb 27KBC Corporation, Ltd. (SHSE:688598) commences an Equity Buyback Plan for CNY 100 million worth of its shares, under the authorization approved on February 23, 2024.KBC Corporation, Ltd. (SHSE:688598) commences share repurchases on February 26, 2024, under the program mandated by the shareholders in the Extraordinary General Meeting held on February 23, 2023. As per the mandate, the company is authorized to repurchase to repurchase CNY 100 million worth of its common shares. The shares will be repurchased at a price of not more than CNY 90 per share. The repurchased shares will be cancelled. The program will be funded out of the company's own funds. The program will be valid till 1 months from the date of approval by shareholders.
Reported Earnings • Feb 24Full year 2023 earnings released: EPS: CN¥1.46 (vs CN¥4.36 in FY 2022)Full year 2023 results: EPS: CN¥1.46 (down from CN¥4.36 in FY 2022). Revenue: CN¥1.07b (down 26% from FY 2022). Net income: CN¥203.3m (down 63% from FY 2022). Profit margin: 19% (down from 38% in FY 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 55% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Chemicals industry in China.
Valuation Update With 7 Day Price Move • Jan 31Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to CN¥45.84, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 14x in the Chemicals industry in China. Total loss to shareholders of 72% over the past year. Simply Wall St's valuation model estimates the intrinsic value at CN¥88.43 per share.
New Risk • Jan 22New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Chinese stocks, typically moving 7.8% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (7.8% average weekly change). High level of non-cash earnings (41% accrual ratio).
Buying Opportunity • Dec 11Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 11%. The fair value is estimated to be CN¥91.03, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 31% over the last 3 years. Earnings per share has grown by 23%. Revenue is forecast to grow by 201% in 2 years. Earnings is forecast to grow by 156% in the next 2 years.
New Risk • Nov 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (41% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (6.9% average weekly change).
Reported Earnings • Oct 24Third quarter 2023 earnings released: EPS: CN¥0.21 (vs CN¥0.98 in 3Q 2022)Third quarter 2023 results: EPS: CN¥0.21 (down from CN¥0.98 in 3Q 2022). Revenue: CN¥271.1m (down 9.7% from 3Q 2022). Net income: CN¥28.8m (down 78% from 3Q 2022). Profit margin: 11% (down from 43% in 3Q 2022). Revenue is forecast to grow 47% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Chemicals industry in China.
공시 • Sep 27KBC Corporation, Ltd. (SHSE:688598) announces an Equity Buyback for CNY 100 million worth of its shares.KBC Corporation, Ltd. (SHSE:688598) announces a share repurchase program. Under the program, the company will repurchase up to CNY 100 million worth of its shares. The program will be valid for a period of 3 months.
Reported Earnings • Aug 15Second quarter 2023 earnings released: EPS: CN¥1.20 (vs CN¥1.39 in 2Q 2022)Second quarter 2023 results: EPS: CN¥1.20 (down from CN¥1.39 in 2Q 2022). Revenue: CN¥304.6m (down 23% from 2Q 2022). Net income: CN¥165.1m (flat on 2Q 2022). Profit margin: 54% (up from 42% in 2Q 2022). Revenue is forecast to grow 40% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China.
공시 • Jun 28KBC Corporation, Ltd. to Report First Half, 2023 Results on Aug 29, 2023KBC Corporation, Ltd. announced that they will report first half, 2023 results on Aug 29, 2023
New Risk • Jun 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (53% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (6.8% average weekly change). Shareholders have been diluted in the past year (17% increase in shares outstanding).
공시 • May 30KBC Corporation, Ltd. (SHSE:688598) announces an Equity Buyback for CNY 100 million worth of its shares.KBC Corporation, Ltd. (SHSE:688598) announces a share repurchase program. Under the program, the company will repurchase up to CNY 100 million worth of its shares. The program will be valid for a period of 3 months.
Reported Earnings • Apr 22Full year 2022 earnings released: EPS: CN¥6.45 (vs CN¥6.26 in FY 2021)Full year 2022 results: EPS: CN¥6.45 (up from CN¥6.26 in FY 2021). Revenue: CN¥1.45b (up 8.4% from FY 2021). Net income: CN¥551.2m (up 10.0% from FY 2021). Profit margin: 38% (in line with FY 2021). Revenue is forecast to grow 44% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Chemicals industry in China.
Reported Earnings • Mar 01Full year 2022 earnings released: EPS: CN¥6.45 (vs CN¥6.26 in FY 2021)Full year 2022 results: EPS: CN¥6.45 (up from CN¥6.26 in FY 2021). Revenue: CN¥1.45b (up 8.4% from FY 2021). Net income: CN¥551.2m (up 10.0% from FY 2021). Profit margin: 38% (in line with FY 2021). Revenue is forecast to grow 38% p.a. on average during the next 2 years, compared to a 19% growth forecast for the Chemicals industry in China.
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent Director Hongbo Liu was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Valuation Update With 7 Day Price Move • Nov 05Investor sentiment improved over the past weekAfter last week's 15% share price gain to CN¥265, the stock trades at a forward P/E ratio of 31x. Average forward P/E is 15x in the Chemicals industry in China.
Reported Earnings • Oct 30Third quarter 2022 earnings released: EPS: CN¥1.46 (vs CN¥1.63 in 3Q 2021)Third quarter 2022 results: EPS: CN¥1.46 (down from CN¥1.63 in 3Q 2021). Revenue: CN¥300.2m (down 20% from 3Q 2021). Net income: CN¥128.8m (down 1.3% from 3Q 2021). Profit margin: 43% (up from 35% in 3Q 2021). The increase in margin was driven by lower expenses. Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China.
Reported Earnings • Aug 29Second quarter 2022 earnings released: EPS: CN¥2.06 (vs CN¥1.58 in 2Q 2021)Second quarter 2022 results: EPS: CN¥2.06 (up from CN¥1.58 in 2Q 2021). Revenue: CN¥396.3m (up 27% from 2Q 2021). Net income: CN¥165.3m (up 30% from 2Q 2021). Profit margin: 42% (up from 41% in 2Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 26%, compared to a 40% growth forecast for the Chemicals industry in China.
Valuation Update With 7 Day Price Move • Aug 02Investor sentiment improved over the past weekAfter last week's 15% share price gain to CN¥381, the stock trades at a forward P/E ratio of 44x. Average forward P/E is 18x in the Chemicals industry in China.
Valuation Update With 7 Day Price Move • Jul 16Investor sentiment improved over the past weekAfter last week's 17% share price gain to CN¥330, the stock trades at a forward P/E ratio of 38x. Average forward P/E is 17x in the Chemicals industry in China.
Valuation Update With 7 Day Price Move • May 02Investor sentiment improved over the past weekAfter last week's 17% share price gain to CN¥214, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 15x in the Chemicals industry in China.
Reported Earnings • Apr 27First quarter 2022 earnings released: EPS: CN¥2.53 (vs CN¥0.97 in 1Q 2021)First quarter 2022 results: EPS: CN¥2.53 (up from CN¥0.97 in 1Q 2021). Revenue: CN¥450.2m (up 126% from 1Q 2021). Net income: CN¥202.7m (up 163% from 1Q 2021). Profit margin: 45% (up from 39% in 1Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 21%, compared to a 43% growth forecast for the industry in China.
Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent Director Hongbo Liu was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Valuation Update With 7 Day Price Move • Mar 08Investor sentiment deteriorated over the past weekAfter last week's 21% share price decline to CN¥222, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 18x in the Chemicals industry in China.
Reported Earnings • Feb 27Full year 2021 earnings: EPS in line with analyst expectations despite revenue beatFull year 2021 results: EPS: CN¥6.26 (up from CN¥2.35 in FY 2020). Revenue: CN¥1.34b (up 214% from FY 2020). Net income: CN¥501.1m (up 197% from FY 2020). Profit margin: 38% (down from 40% in FY 2020). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 9.7%. Over the next year, revenue is forecast to grow 27%, compared to a 47% growth forecast for the industry in China.
Valuation Update With 7 Day Price Move • Jan 11Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to CN¥298, the stock trades at a forward P/E ratio of 43x. Average forward P/E is 20x in the Chemicals industry in China.